KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Charles River Laboratories International (CRL) Non-Current Deffered Revenue: 2010-2011

Charles River Laboratories International's Non-Current Deffered Revenue was N/A to $25.4 million in Q3 2011 from the same period last year, while for Sep 2011 it was $25.4 million, marking a year-over-year change of. This contributed to the annual value of $24.7 million for FY2010, which is N/A change from last year.
Per Charles River Laboratories International's latest filing, its Non-Current Deffered Revenue stood at $25.4 million for Q3 2011, which was up 1.05% from $25.2 million recorded in Q2 2011.
Charles River Laboratories International's 5-year Non-Current Deffered Revenue high stood at $25.4 million for Q3 2011, and its period low was $24.7 million during Q4 2010.
Moreover, its 2-year median value for Non-Current Deffered Revenue was $25.2 million (2011), whereas its average is $25.1 million.